| CAS NO: | 81-27-6 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| Molecular Weight (MW) | 862.74 |
|---|---|
| Formula | C42H38O20 |
| CAS No. | 81-27-6 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 125 mg/mL |
| Water: N/A | |
| Ethanol: N/A | |
| SMILES | OC1C(O)C(OC2=C(C(C(C(O)=CC(C(O)=O)=C3)=C3C4C5C(C=CC=C6OC7C(O)C(O)C(O)C(CO)O7)=C6C(C8=C5C=C(C(O)=O)C=C8O)=O)=O)C4=CC=C2)OC(CO)C1O |
| Synonyms | NSC112929; NSC-112929; Sennoside A; NSC 112929; |
| In Vitro | In vitro activity: Sennoside A, a kind of irritant laxative isolated from rhei rhizome, causes purgative actions in the intestine through regulating the spontaneous motility of colon. It mildly inhibits bovine serum monoamine oxidase with IC50 of 17 μM. Kinase Assay: The gastroprotective activities of sennoside A was found to be due to the up-regulation of PGE2 and the inhibitions of H+/K+-ATPase activity. When measured the H+/K+-ATPase activities of sennoside A, the positive control exhibited inhibitions of 41.1% and 42.4% at 50 μM and 100 μM, whereas sennoside A showed dose-dependent inhibitions of 17.3% and 27.1% at 50 μM and 100 μM. |
|---|---|
| In Vivo | In a rat model, sennoside A reduced gastric juice, total acidity and increased pH, indicating that proton pump inhibition reduces gastric acid secretion. Furthermore, sennoside A increased PGE2 in a concentration-dependent manner. Moreover, in the intestinal transporting and gastric emptying rate experiment, sennoside A was found to accelerate such GI motility. These results suggested sennoside A possessed significant gastroprotective activities and it might be useful for the gastric disease treatment. |
| Animal model | Rats |
| Formulation & Dosage | N/A |
| References | Chem Pharm Bull (Tokyo). 1989 Oct;37(10):2744-6; Basic Clin Pharmacol Toxicol. 2007 Aug;101(2):121-6; Biomol Ther (Seoul). 2015 Sep;23(5):458-64. |
m.cnreagent.com